These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29298624)

  • 1. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
    de Lemos ML; Kung C; Kletas V; Badry N; Kang I
    J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing Practices of QT Interval Prolonging Drugs in Critically Ill Older Adults in South India.
    Moolambally SR; Malik A; Boloor A A
    Kathmandu Univ Med J (KUMJ); 2023; 21(83):298-303. PubMed ID: 39206650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and determinants of QT interval prolongation in medical inpatients.
    Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
    Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long QTc and torsades de pointes in human immunodeficiency virus disease.
    Kocheril AG; Bokhari SA; Batsford WP; Sinusas AJ
    Pacing Clin Electrophysiol; 1997 Nov; 20(11):2810-6. PubMed ID: 9392812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
    Khan Q; Ismail M; Haider I; Ali Z
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT Prolongation and Oncology Drug Development.
    Fradley MG; Moslehi J
    Card Electrophysiol Clin; 2015 Jun; 7(2):341-55. PubMed ID: 26002398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
    Khan Q; Ismail M; Haider I
    Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.
    Khan F; Ismail M; Khan Q; Ali Z
    Expert Opin Drug Saf; 2018 Oct; 17(10):1029-1039. PubMed ID: 30193085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QT prolongation and safety in the Indian population.
    Dabhi J; Mehta A
    Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.
    Fan W; Liu H; Shen Y; Hong K
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
    Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.
    Pickham D; Helfenbein E; Shinn JA; Chan G; Funk M; Weinacker A; Liu JN; Drew BJ
    Crit Care Med; 2012 Feb; 40(2):394-9. PubMed ID: 22001585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.